This episode of Lung Cancer Considered reviews new and upcoming approvals for subcutaneous immune checkpoint inhibitors. Join host Dr. Narjust Florez and guests, Dr. Cheryl Ho and Dr. Maria Velez Velez, for a discussion of the formulation and its place in the management of patients with lung cancer. 

Guests:

Cheryl Ho, MD, FRCPC
Thoracic Oncologist, BC Cancer
Clinical Associate Professor and Fellowship Program Director
University of British Columbia

Maria Velez Velez, MD, MS
Clinical Instructor, Division of Hematology/Oncology
David Geffen School of Medicine at UCLA

This episode of Lung Cancer Considered reviews new and upcoming approvals for subcutaneous immune checkpoint inhibitors. Join host Dr. Narjust Florez and guests, Dr. Cheryl Ho and Dr. Maria Velez Velez, for a discussion of the formulation and its place in the management of patients with lung cancer. Guests: Cheryl Ho, MD, FRCPC Thoracic Oncologist, BC Cancer Clinical Associate Professor and Fellowship Program Director University of British Columbia Maria Velez Velez, MD, MS Clinical Instructor, Division of Hematology/Oncology David Geffen School of Medicine at UCLA

IASLC Lung Cancer Considered: FDA Approval: Subcutaneous Immunotherapy

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda

Science

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda

Share IASLC Lung Cancer Considered: FDA Approval: Subcutaneous Immunotherapy

Sign up to save your podcasts

IASLC Lung Cancer Considered: FDA Approval: Subcutaneous Immunotherapy

IASLC Lung Cancer Considered: FDA Approval: Subcutaneous Immunotherapy

More shows like Lung Cancer Considered

Marketplace

NPR News Now

WSJ What’s News

NEJM This Week

JAMA Clinical Reviews

Lung Cancer Update

Research To Practice | Oncology Videos

The Daily

Up First from NPR

OncLive® On Air

The Journal.

Conversations in Lung Cancer Research

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions

Lung Cancer Rx